Serum secreted phospholipase A2 is associated with abdominal aortic aneurysm presence but not progression

Atherosclerosis

Volumn 216, Issue 2, 2011, Pages 458-460

  Golledge, Jonathan ^a   Mallat, Ziad ^b,c   Tedgui, Alain ^b   Norman, Paul E ^d  

^a JAMES COOK UNIVERSITY   (Australia)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Abdominal aortic aneurysm; Biomarker; Secretory phospholipase A2

Indexed keywords

PHOSPHOLIPASE A2;

ABDOMINAL AORTA ANEURYSM; AGED; ARTICLE; DISEASE COURSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

AGED; AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FLUOROMETRY; HUMANS; MALE; PHOSPHOLIPASES A2, SECRETORY; REGRESSION ANALYSIS; RISK FACTORS; ROC CURVE;

EID: 79958011294     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.022     Document Type: Article

References (13)

1. Collaborative Aneurysm Screening Group A comparative study of the prevalence of abdominal aortic aneurysms in the United Kingdom, Denmark and Australia. J Med Screen 2001, 8:46-50.
2. Golledge J., Norman P.E. Pathophysiology of abdominal aortic aneurysm relevant to improvements in patients' management. Curr Opin Cardiol 2009, 24:532-538.
3. Oestvang J., Johansen B. PhospholipaseA2: a key regulator of inflammatory signalling and a connector to fibrosis development in atherosclerosis. Biochim Biophys Acta 2006, 1761:1309-1316.
4. Mallat Z., Lambeau G., Tedgui A. Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010, 122:2183-2200.
5. Fraser H., Hislop C., Christie R.M., Rick H.L., Reidy C.A., Chouinard M.L., Eacho P.I., Gould K.E. Trias J Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol. 2009, 53:60-65.
6. Zack M., Boyanovsky B.B., Shridas P., Bailey W., Forrest K., Howatt D.A., Gelb M.H., de Beer F.C., Daugherty A., Webb N.R. Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice. Atherosclerosis 2010, 53(August). [Epub ahead of print].
7. Norman P.E., Flicker L., Almeida O.P., Hankey G.J., Hyde Z., Jamrozik K. Cohort profile: The Health In Men Study (HIMS). Int J Epidemiol 2009, 38:48-52.
8. Golledge J., Biros E., Cooper M., Warrington N., Palmer L.J., Norman P.E. Apolipoprotein E genotype is associated with serum C-reactive protein but not abdominal aortic aneurysm. Atherosclerosis 2010, 209:487-491.
9. Mallat Z., Benessiano J., Simon T., Ederhy S., Sebella-Arguelles C., Cohen A., Huart V., Wareham N.J., Luben R., Khaw K.T., Tedgui A., Boekholdt S.M. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007, 27:1177-1183.
10. Rosengren B., Jönsson-Rylander A.C., Peilot H., Camejo G., Hurt-Camejo E. Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis. Biochim Biophys Acta 2006, 1761:1301-1308.
11. Tsimikas S., Mallat Z., Talmud P.J., Kastelein J.J., Wareham N.J., Sandhu M.S., Miller E.R., Benessiano J., Tedgui A., Witztum J.L., Khaw K.T., Boekholdt S.M. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010, 56:946-955.
12. Golledge J., Norman P.E. Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors?. Arterioscler Thromb Vasc Biol 2010, 30:1075-1077.
13. Thompson A.R., Drenos F., Hafez H., Humphries S.E. Candidate gene association studies in abdominal aortic aneurysm disease: a review and meta-analysis. Eur J Vasc Endovasc Surg 2008, 35:19-30.